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Over the past 5 months, the coronavirus disease 2019 (COVID19) pandemic has relentlessly impacted the global population. The first case of COVID19 infection was identified in the Wuhan City of China on December 1, 2019. Since then, the virus has spread to 213 countries and territories, resulting in over 5.3 million confirmed cases and over 340,000 deaths as on May 23, 2020 (<https://www.worldometers.info/coronavirus/>). People of all ages are vulnerable to COVID19 infection; however, those over 60 years of age and with pre-existing medical conditions, such as cardiovascular disease, diabetes, or high blood pressure, are more prone to fall seriously ill and succumb to the disease. According to the Centers for Disease Control and Prevention, the symptoms of COVID19 include fever, cough, and shortness of breath, fatigue and sudden loss of sense of smell and taste in some cases (<https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>), though its typical characteristic is pneumonia that requires hospitalization and even death, if not intervened timely.

For any therapeutic intervention, the pathological cascade involved in a disease needs to be elucidated. Therefore, identifying the SARS-CoV-2 virus receptor recognition mechanism that regulates its virulence and pathogenesis holds the key to confront the COVID19 epidemic \[[@CR1]\]. Structural analysis of SARS-CoV-2 revealed that the enveloped, positive-sense, single-stranded RNA viruses belong to the genus β-coronavirus and have azoonotic origin \[[@CR2]\]. Mounting evidence suggests that SARS-CoV-2 primarily spreads through the respiratory tract, either in the form of droplets, respiratory secretions, or direct contact \[[@CR3]\]. In addition, the abundant presence of ACE2 protein receptor in lung alveolar epithelial cells facilitates the binding of SARS-CoV-2 spike-S-glycoprotein, and thus, expedites viral infection. This interaction also activates distinct cytokines crucial for antiviral responses. The data of critically severe COVID19 patients revealed the presence of IL-2, IL-6, IL-7, IL-10, TNF-α, GCSF, MCP-1, MIP-1α, and TNF-α \[[@CR4]\] to name a few. To date, no specific approved antiviral therapy for the treatment of COVID19 infection is available, except standard supportive care e.g., oxygenation, ventilation, and fluid management, etc., and some non-specific treatments e.g., hydroxychloroquine and chloroquine etc., to ameliorate the symptoms, and some antivirals and protease inhibitors. Thus, to reverse or combat the detrimental effect produced by SARS-CoV-2 virus, there is an urgent need for a reliable therapy. In this context, multipotent mesenchymal stem cells (MSCs) have shown a strong safety and efficacy profile as they have been intensively investigated in preclinical and clinical studies of various lung diseases, including respiratory virus-induced acute respiratory distress syndrome (ARDS) \[[@CR5], [@CR6]\]. Over the past years, the MSCs infusion exhibited an excellent safety record as evident in the 871 clinical trials registered in the National Institute of Health database (<https://clinicaltrials.gov/ct2/results?cond=Mesenchymal+Stem+Cells&term=&cntry=&state=&city=&dist=>), including 117 trials (<https://clinicaltrials.gov/ct2/results?cond=mesenchymal+stem+cell&term=pulmonary&cntry=&state=&city=&dist=&Search=Search>) on pulmonary complications, to date. On the other hand, 2845 COVID19 trials worldwide as of 23 May 2020 at World Health Organization-International Clinical Trial Registry Platform (<https://www.who.int/ictrp/en/>) and 29 clinical trials on MSCs and COVID19 as of 23 May 2020 (<https://clinicaltrials.gov/ct2/results?cond=mesenchymal+stem+cell&term=COVID19&cntry=&state=&city=&dist=&Search=Search>) have been registered at the NIH database. Worth mentioning, that out of 29 clinical trials, one has been withdrawn (trial no. NCT04293692), therefore, as yet, 28 trials have been registered with a participation of approximately 1525 patients. All of the mentioned studies that employ MSCs and COVID19 patients are in early-phase, and either recruiting or yet to recruit the participants.

To brief, out of the twenty-four clinical trials UC-MSCs will be utilized in eleven clinical trials, and AD-MSCs will be utilized in six trials, two will employ DPSCs, one with OM-MSCs, three on BM-MSC, and one (NCT04276987) will utilize exosomes derived from allogenic adipose mesenchymal stem cells, also the trail no. NCT043660663, with 60 participants, will be utilizing the MSC-derived exosomes in twenty participants (20/60), twenty will receive MSC only (20/60), and the rest twenty will be treated as control (20/60). Four registries do not reveal the tissue source (Table [1](#Tab1){ref-type="table"}). The minimum age eligibility criteria in all the trials are 18 years, except the trial no. NCT04349631, NCT04362189, and NCT03042143 where child, adult, or aged, all are eligible to get enrolled as participants. None of the above studies have gender restriction, and the minimum follow-up time is 3 months for each of these investigations. The above registries indicate that a majority of studies will employ umbilical cord-derived MSC which seems reasonable for the following reasons: ease of harvest, fast doubling time, high scalability, and since umbilical cord has a high concentration of stem cells, they can provide a large amount of cells. Noteworthy they have faster doubling times, more plasticity, and with no tumorigenicity \[[@CR7], [@CR8]\]. They are derived from a discarded tissue, and so have less ethical concern. In our opinion and experience, amongst the cell types used, equally desirable cell type for COVID19 patients is DPSCs, since they too appear to have similar advantages like UC-MSCs. Some of the unique advantages associated with DPSCs are noninvasive isolation, ease of harvest, and easy accessibility, as they reside in the impacted third molar; beside strong therapeutic ability are the key advantages of DPSCs \[[@CR9]\]. They show clonogenicity, and higher ex-vivo proliferative capacity \[[@CR10]\] compared with MSCs; they are less prone to malignancy \[[@CR11]\], and therefore can give rise to sufficient numbers of cells for cell therapy. Compared with umbilical cord stem cells, DPSCs demonstrated delayed cellular senescence \[[@CR12]\] which can be correlated to the increased expression of genes related to growth factors \[[@CR13]\]. They have minimal ethical concerns, which is otherwise a hurdle often associated with other cell types. In the presence of specific stimuli, they can give rise to several cell types \[[@CR14], [@CR15]\]. As per our knowledge, to date, there is only a single pre-clinical investigation \[[@CR6]\], apart from a case report \[[@CR16]\] that supports the rationale for the use of MSCs in COVID19. Interestingly, the Abu Dhabi Stem Cell Center (ADSCC), UAE has recently supervised a clinical trial on 73 COVID19 patients employing 'Activated' MSCs. The study claims that all the participants were successfully treatment and cured relieved of symptoms of the virus by inhaling the treatment into their lungs after it has been nebulized into a fine mist (<https://www.khaleejtimes.com/coronaviruspandemic/coronavirus-uaes-stem-cell-treatment-fights-symptoms-of-covid-19-not-cure-it-->). The source of the MSCs was patients own blood. However, no further information has been provided, therefore, more detailed information regarding the procedure of stem cell processing and priming, dose and timing of MSCs inhalation, patients' age and gender, and the follow-up is needed to determine the efficacy of MSCs activation on those patients.Table 1Systematic representation of the clinical trials of COVID19 and MSC or their derivatives registered with NIH, USA till 23.05.2020[S.No.Clinical trial numberStudy TitlePhaseStatusSample Size(n)Cellular]{.ul}\
[InterventionsDate of Start (DOS)]{.ul}\
[Date of Completion (DOC)Gender]{.ul}\
[(Male/Female/ Both)AgeCountry]{.ul}1-NCT04315987Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 PneumoniaINot Recruiting66Nest Cell ®DOS: April 2020DOC: June 2020Both18 Yrs. and olderBrazil2-NCT04313322Treatment of COVID19 Patients Using Wharton's Jelly- Mesenchymal Stem CellsIRecruiting5WJ-MSCsDOS: March 2020DOC:September 2020Both18 Yrs. and olderJordan3-NCT04288102Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19)IIRecruiting90MSCsDOS: March 2020DOC: July 2020Both18 to75 Yrs.China4-NCT04302519Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem CellsEarly phaseINot Recruiting24DPSCsDOS: March 2020DOC: July 2021Both18 to75 Yrs.--5-NCT04252118Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel CoronavirusIRecruiting20MSCsDOS: January 2020DOC: December 2021Both18 to70 Yrs.China6-NCT04273646Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia--Not Recruiting48UC-MSCsDOS: April 2020DOC: February 2022Both18 to 65 Yrs.China7-NCT04276987A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus PneumoniaINot Recruiting30Exosomes derived from AD-MSCs(MSCs-Exo)DOS: February 2020DOC: July 2020Both18 to75 Yrs.--8-NCT04336,254Safety and EfficacyStudy of AllogeneicHuman Dental PulpMesenchymal StemCells to Treat SevereCOVID19 PatientsI and IIRecruiting20DPSCsDOS: April 2020DOC: March2021Both18 to 65 Yrs.China9-NCT04339,660Clinical Research of Human MesenchymalStem Cells in the Treatment of COVID19 PneumoniaI and IIRecruiting30UC-MSCsDOS: February 2020DOC: June 2020Both18 to 75 Yrs.China10-NCT04346,368Bone Marrow-DerivedMesenchymal StemCell Treatment forSevere Patients WithCoronavirus Disease2019 (COVID19)I and IINotRecruiting20BM-MSCsDOS: April 2020DOC: December2020Both18 to 75 Yrs.China11-NCT04352,803Adipose MesenchymalCells for Abatement ofSARS CoV-2RespiratoryCompromise inCOVID-19 DiseaseINot Recruiting20AD-MSCsDOS: April 2020DOC: April 2026Both18 to 90 Yrs.--12-NCT04349,631A Clinical Trial toDetermine the Safetyand Efficacy of HopeBiosciencesAutologousMesenchymal StemCell Therapy (HBadMSCs)to ProvideProtection AgainstCOVID19IIEnrolling byinvitation56AD-MSCsDOS: May 2020DOC: December 2020BothChild, Adult,OlderAdultUnited States13-NCT03042,143Repair of AcuteRespiratory DistressSyndrome by StromalCell Administration(REALIST) (COVID19)(REALIST)I and IIRecruiting75UC derived CD362 enriched MSCsDOS: January 2019DOC: October 2022Both16 Yrs. and olderUnited Kingdom14-NCT04390,152Safety and Efficacy of Intravenous Wharton'sJelly DerivedMesenchymal StemCells in AcuteRespiratory DistressSyndrome due to COVID19I and IINot Recruiting40WJ-MSCsDOS: June 2020DOC: May 2021Both18 to 80 Yrs.Colombia15-NCT04382,547Treatment ofCOVID19 AssociatedPneumonia withAllogenic PooledOlfactory MucosaderivedMesenchymalStem CellsI and IINot Recruiting40OM-MSCsDOS: May 2020DOC: June 2021Both18 to70 Yrs.Belarus16-NCT04366,323Clinical Trial to Assessthe Safety andEfficacy of IntravenousAdministration of Allogeneic AdultMesenchymal StemCells of ExpandedAdipose Tissue in Patients with Severe Pneumonia due to COVID19I and IINot Recruiting26AD-MSCsDOS: April 2020DOC: October 2021Both18 to 80 Yrs.--17-NCT04366,063Mesenchymal StemCell Therapy for SARS-CoV-2-relatedAcute RespiratoryDistress SyndromeII and IIIRecruiting60MSCs, and Exosomes derived from MSCs (MSCs-Exo)DOS: April 2020DOC: December 2020Both18 to 65 Yrs.Iran18-NCT04377,334Mesenchymal StemCells (MSCs) in Inflammation-Resolution Programsof CoronavirusDisease 2019(COVID19) InducedAcute RespiratoryDistress Syndrome(ARDS)IINot Recruiting40BM-MSCsDOS: May 2020DOC: February 2021Both18 Yrs. and olderGermany19-NCT04371,393MSCs in COVID19ARDSIIIRecruiting300MSCsRemestemcel-LDOS: April 30, 2020DOC: April 2022Both18 Yrs. and olderUnited States20-NCT04362,189Efficacy and SafetyStudy of AllogeneicHB-adMSCs for the Treatment of COVID19IINot Recruiting110AD-MSCsDOS: May 2020DOC: October 2020BothChild,Adult,OlderAdultUnited States21-NCT04366,271Clinical Trial ofAllogeneicMesenchymal Cellsfrom Umbilical CordTissue in Patients withCOVID19IIRecruiting106UC-MSCsDOS: May 2020DOC: May 2021Both40 to 80 Yrs.Spain22-NCT04348,435A Randomized,Double-Blind,Placebo-ControlledClinical Trial to Determine the Safety and Efficacy of HopeBiosciencesAllogeneicMesenchymal StemCell Therapy (HBadMSCs) to Provide Protection Against COVID19IIEnrolling by invitation100AD-MSCsDOS: April 2020DOC: April 2021BothChild,Adult, OlderAdultUnited States23-NCT04371,601Safety and Effectiveness of Mesenchymal StemCells in the Treatment of Pneumonia of Coronavirus Disease 2019Early Phase IActive not Recruiting60UC-MSCsDOS: March 2020DOC: December 2022Both18 to 70 Yrs.China24-NCT04355,728Use of UC-MSCs for COVID19 PatientsI and IIRecruiting24UC-MSCsDOS: April 2020DOC: May 2021Both18 Yrs. and olderUnited States25-NCT04392,778Clinical Use of StemCells for the Treatment of COVID19I and IIRecruiting30UC-MSCsDOS: April 2020DOC: September 2020Both40 to 60 Yrs.Turkey26-NCT04397,796Study of the Safety of Therapeutic Tx with Immunomodulatory MSC in Adults with COVID19 Infection Requiring Mechanical VentilationINot Recruiting45BM-MSCsDOS: June 2020DOC: June 2021Both18 to 80 Yrs.--27-NCT04390,139Efficacy and SafetyEvaluation of Mesenchymal StemCells for the Treatment of Patientswith RespiratoryDistress to COVID19I and IIRecruiting30WJ-MSCsDOS: May 2020DOC: December 2020Both18 to 75 Yrs.Spain28-NCT04269,525Umbilical Cord (UC)- Derived MesenchymalStem Cells (MSCs)Treatment for the 2019-novel Coronavirus (nCOV) PneumoniaIIRecruiting10UC-MSCsDOS: February 2020DOC: September 2020Both18 to 75 Yrs.China

Interestingly, the data obtained from a single-center, open-labeled pilot investigation in COVID19 patients from China demonstrated that the treatment with MSCs improved disease-associated parameters in severe and critically severe patients \[[@CR16]\]. To brief, seven patients (one critically severe, four severe, and two having common symptoms of pneumonia) were enrolled in the treatment group, where as three patients served as placebo controls (all displaying severe symptoms). All treated patients received a single dose of 1X10^6^ MSCs/kg body weight. Remarkably, all seven showed improvement over two weeks with no noticeable adverse effect, thereby, demonstrated the safe and effective infusion of ACE2^--ve^ MSCs in COVID19 pneumonia patients. The overall improvement in the MSCs infused group was striking as within 2 days after treatment pulmonary functions and symptoms of all the seven patients significantly improved, and most tested negative for the SARS-CoV-2 nucleic acid test over two weeks after MSCs infusion. After 6 days of infusion, the therapy inhibited the over-activation of the immune system by inhibiting CXCR3^+^CD4^+^ T cells, CXCR3^+^CD8^+^ T cells, and CXCR3^+^ NK cells. It also decreased TNF-α and enhanced the number of peripheral lymphocytes, CD14^+^CD11c^+^CD11^bmid^ regulatory DC, and anti-inflammatory cytokine IL-10. Moreover, the gene expression profile revealed that MSC was ACE2^-ve^ and TMPRSS2^-ve^, which indicates that the MSCs would not be susceptible to SARS-CoV2 infection. Finally, the RNA sequencing and gene expression analysis showed that MSCs were closely involved in the anti-viral pathways, and had anti-inflammatory trophic activities \[[@CR6]\]. In line with above findings, the results from a case report on COVID19 \[[@CR16]\] and a study on influenza virus H9NA \[[@CR5]\], which shares complications similar to COVID19 like ARDS and lung failure, demonstrated that MSCs can offer therapy for virally-induced pulmonary complications in clinical settings. While all these studies have provided new insights into the protective mechanism of MSCs during viral infection, a few short comings were noticed in these treatments. For example, similar to study conducted by ADSCC, there is also a lack of information on MSCs processing and screening before infusion, and the long-term follow-up of patients etc. For a protocol to be implicated in a larger cohort, optimal information regarding MSCs as well as patients needs to be investigated in a rationally designed controlled setting. Concerning the underlying mechanism by which MSCs exert a beneficial effect, the ability to home \[[@CR17]\], engraft \[[@CR17]\] and transdifferentiate into the target tissue, which is the infected lung in the present case, besides the bystander effect and immunomodulatory potential \[[@CR9], [@CR18], [@CR19]\], are well documented. Also, the anti-apoptotic, anti-viral, and anti-bacterial functions of this therapy have been well known \[[@CR20]\]. Under homeostatic conditions, MSCs are hypo-immunogenic and have immune evasion capabilities \[[@CR21]\], indicating their suitability for allogeneic transplantation.

Despite years of success in MSC research, some of the challenges faced for successful transplantation therapy include heterogeneous treatment response, low number, and source-specific immunomodulatory response \[[@CR22]\]. Interestingly, the reparative effects noticed in vivo indicate that clinical efficacy depends on the microenvironment of the transplants \[[@CR23]\]. Therefore, the therapeutic capability of MSCs can be regulated and is an attractive area for investigation. However, resting stage MSCs do not show the above potentials; it is only when they are exposed to a stimuli milieu, they demonstrate immunomodulatory or homing potentials \[[@CR24], [@CR25]\]. This indicates that the modulatory activity is not constitutively expressed by MSCs but is determined by the process of 'priming' to be obtained. Therefore, the empowerment of MSCs by priming before a clinical application may be a potential solution to overcome the challenges that hinder the effectiveness of MSC outcomes. Priming, with inflammatory cytokines, is a process to modulate biological, biochemical or biophysical features that can influence cell fate \[[@CR26], [@CR27]\]. In recent years, several approaches have been proposed to improve the effectiveness, endurance and therapeutic efficiency of MSCs \[[@CR28], [@CR29]\]. Worth mentioning, the approaches utilizing MSCs, and especially the primed MSCs, could be vital for the success of cell therapy in lung complications, as the intravenously infused MSCs often get trapped in the lung; however, the retention time of MSCs within the lung is extremely short \[[@CR30]\]. Though, the alteration in holding capacity of lung in a diseased scenario cannot be ruled out. As primed MSCs could efficiently enhance retention \[[@CR31]\], beside intensifying homing \[[@CR17]\], and survival \[[@CR32]\] in damaged lung, therefore, activation via priming could be a crucial mechanism for retention and engraftment of MSCs in a diseased lung, subsequently providing benefits to the lung through multiple mechanisms.

Priming perspectives and MSCs robustness are currently under development. Pre-treating MSCs before injection may enhance the expression of fitness markers and stimulate greater therapeutic outcome. For instance, reports suggest cytokine mediated activation of MSCs lead to strong immunosuppressive behavior, and thereby attenuation of lung injury in rodents \[[@CR31], [@CR33]\], however some contradictory findings are also available as no effective role of proinflammatory cytokine priming was observed on MSCs in a model of acute lung injury and ARDS \[[@CR34]\]. Therefore, the effect of cytokine priming needs to be further verified to prove the efficacy of primed MSCs in lung anomalies. Besides cytokines, priming of MSCs by growth factors is also a potent mechanism for MSC activation before infusion in pulmonary diseases \[[@CR35]\]. Likewise, hypoxia preconditioning can also improve the proliferation and therapeutic efficacy of MSCs, as evident in bleomycin-induced pulmonary fibrosis model \[[@CR36]\]. Further, employing pharmacological agents such as paclitaxel to prime MSCs could also be helpful in improving lung anomalies \[[@CR37]\]. Therefore, in line with above findings it could reasonably by presume that MSC priming is a significant approach for treating pulmonary anomalies. In the light of above findings, herein, we propose that the mechanism of priming of MSC could be implied to the following: i) Licensing by pro-inflammatory cytokines such as IFN-γ, TNF-α, etc., to enhance immunosuppressive potential; ii) Priming by non-cytokines stimuli such as hormones/growth factors like HGF to boost defensive and protective cellular mechanisms; iii) Pre-conditioning by hypoxia, and/or pharmacological agents, e.g., sphingosine-1-phosphate, etc., to enhance engraftment and reparative effects; iv) Activation by spheroid culturing to enhance homing, survival, differentiation, and lineage specificity e.g. angiogenic mechanism; v) The timing of MSCs engraftment and engagement in the process of activation of immune cells to achieve the most excellent beneficial effect of MSCs infusion.

Nevertheless, there are several limitations associated with the priming approaches that may jeopardize MSC based therapies at clinics; hence these challenges must be overcome to harness the true potential of MSCs. For instance, the priming of MSCs by proinflammatory cytokines may negatively affect the MHC class I and class II level; Hormones and/or growth factors may affect the differentiation capacity of MSCs; Priming by hypoxia may induce oxidative stress in MSCs; Growth factors may negatively affect the differentiation capacity of MSCs; Spheroid cultures owing to the variability in their size may lead to the necrotic spheroid core, thus, may interfere with the effectiveness of MSCs after transplantation. Further, the variations in results due to the heterogeneous nature of MSCs \[[@CR23]\], and high cost associated with priming protocols, etc., are the considerable hindrances in the successful translation of primed MSCs to the clinic. For instance, not all the priming stimulus, even the same stimuli, shows a similar effect on the cells. Therefore, the effect of individual licensing stimuli should be accessed before being employed at a manufacturing scale. For example, IFN-γ can inhibit T cell proliferation in the regulation of MSC-mediated immunosuppression \[[@CR38]\] and can also increase the capacity of MSCs to produce different subtypes of Tregs \[[@CR39]\]. IFN-γ can also promote increased expressions of VCAM-1 and ICAM-1 on the surface of MSCs \[[@CR40]\]. Similarly, the adjustment of MSC infusion timing may reveal the accurate description of inflammatory surroundings related to a specific disease \[[@CR41]\]. This may also explain why MSCs do not always exhibit beneficial effects, even in the same disease. Therefore, it is of great importance to choose the right stimuli in the right dose at and for the right timing, besides fitness of MSCs, fresh vs. cryopreserved, MSCs passage number, and route of delivery to assure homogenous clinical outcomes (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Schematic of SARS-CoV-2 infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (**a**) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (**b**) Primed MSCs, (**c**) SARS-CoV-2 and 'Primed MSCs' post-infusion in the lung, (**d**) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis, homing, anti-apoptotic, and anti-microbial activities)

To conclude, since its emergence, COVID19 has turned out to be the top priority of the healthcare system. Although stem cell treatment has not yet been proven to eliminate coronavirus completely, preliminary results are promising, suggesting that the diseased patients, under the treatment, might be more amenable to survive the infection. The effect of priming on MSCs' therapeutic potential has been extensively researched and continues to be investigated. The results of such efforts are eagerly anticipated, as these will pave a way for a strong foundation for future scientific research and clinical applications for a variety of diseases including pulmonary complications. Finally, bearing in mind the desires for mitigation of the existing pandemic, the effectiveness of MSCs in virally infected acute respiratory diseases symptoms, and the pieces of evidence from priming strategies for MSCs, we hypothesize that endorsing priming may enhance the effectiveness of MSCs for long-term benefits which is a prerequisite for the success of stem cell therapy in COVID19 patients.
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